Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 514 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft Versus Host Disease Oral Clear all
Completed Phase 1 Interventional

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
Drug
Lead sponsor
Nucorion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Monterey Park, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 14, 2026, 10:14 AM EDT
Not listed Phase 3 Interventional

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

NCT02504008
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy
Interventions
AXS-02 (oral zoledronate), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
29
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Encinitas, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 14, 2026, 10:14 AM EDT
Completed No phase listed Observational

International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430

NCT01056848
View directory record Official record
Conditions
Hyponatremia With Normal Extracellular Fluid Volume, Hyponatremia With Excess Extracellular Fluid Volume
Interventions
Not listed
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
Lomita, California • Clearewater, Florida • Fleming Island, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced Oct 14, 2026, 10:14 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01155375
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT00696020
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
22
States / cities
Riverside, California • San Diego, California • Wheat Ridge, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 14, 2026, 10:14 AM EDT
Recruiting Phase 1 Interventional

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

NCT04260022
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
Interventions
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

Managing Post-operative Pain in Children With Cerebral Palsy Using a Pain Pump

NCT00884650
View directory record Official record
Conditions
Cerebral Palsy
Interventions
oral analgesic, intravenous analgesic per pump
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

NCT01533922
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Tiotropium, Olodaterol, Tiotropium + Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00720499
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 14, 2026, 10:14 AM EDT
Terminated Phase 1 Interventional

Study of GBT021601 in Participants With Renal Impairment

NCT05878704
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT021601
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

NCT04142762
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

NCT01932970
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
40
States / cities
Alhambra, California • Azusa, California • Bakersfield, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 14, 2026, 10:14 AM EDT
Withdrawn Phase 1 Interventional

Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache

NCT04353505
View directory record Official record
Conditions
Chronic Migraine, Cluster Headache, Trigeminal Neuralgia
Interventions
Ketorolac, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01381094
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Pine Bluff, Arkansas • Covina, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 14, 2026, 10:14 AM EDT
Not listed Phase 3 Interventional

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

NCT00020605
View directory record Official record
Conditions
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naloxone hydrochloride
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 14, 2026, 10:14 AM EDT
Terminated Not applicable Interventional

A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery

NCT03244683
View directory record Official record
Conditions
Pancreatic Cancer, Chronic Pancreatitis
Interventions
Ensure Surgical, Nutrition counseling, Low-intensity exercise therapy
Dietary Supplement · Other
Lead sponsor
Ohio State University
Other
Eligibility
40 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Pomalidomide for Chronic Graft-versus-Host Disease

NCT01688466
View directory record Official record
Conditions
Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity

NCT00607542
View directory record Official record
Conditions
Spasticity, Cerebral Palsy
Interventions
baclofen
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 16 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 14, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT02569437
View directory record Official record
Conditions
Polyp of Nasal Sinus
Interventions
Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

NCT05035641
View directory record Official record
Conditions
Renal Anemia
Interventions
AND017, Placebo
Drug
Lead sponsor
Kind Pharmaceuticals LLC
Industry
Eligibility
20 Years to 74 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Northridge, California • Winter Park, Florida • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431274
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 14, 2026, 10:14 AM EDT
Terminated Phase 4 Interventional

Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation

NCT01513031
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Education and telephone follow-up
Other
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

NCT00003735
View directory record Official record
Conditions
Leukemia
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
35
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 14, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091
View directory record Official record
Conditions
Long COVID
Interventions
Nirmatrelvir, Ritonavir, Placebo
Drug
Lead sponsor
Harlan M Krumholz
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 14, 2026, 10:14 AM EDT